Nuria Alonso *

Autora invitada por SIIC

Efectos sobre el perfil bioquímico, los síntomas clínicos y la calidad de vida

TRATAMIENTO SUSTITUTIVO EN LA INSUFICIENCIA ADRENAL PRIMARIA. EFECTOS DE DOS PAUTAS DE TRATAMIENTO

Los pacientes tratados con una pauta alternativa de hidrocortisona muestran un perfil bioquímico de cortisol más fisiológico que con la pauta clásica, aunque la percepción general de calidad de vida aparece un poco deteriorada.

*Nuria Alonso
describe para SIIC los aspectos relevantes de su trabajo
EVALUATION OF TWO REPLACEMENT REGIMENS IN PRIMARY ADRENAL INSUFFICIENCY PATIENTS
Institución principal de la investigación
*Hospital Universitari Germans Trias i Pujol, Badalona, España, Badalona, España
Imprimir nota

Referencias bibliográficas
1 Ten S, New M, Maclaren N. Addison’s Disease 2001. Clincal Review 130. J Clin Endocrinol Metab 2001, 86:2909-2922.2 Besser GM & Jeffcoate WJ.Endocrine and metabolic disease: adrenal diseases. Br Med J 1976, 1: 448-451.3 Burke CW. Primary adrenocortical failure. In: A. Grossman ed. Clinical Endocrinology. 1st ed. Oxford: Blackwell Scientific Publications.1992: 393-404.4 Thorn GW, Lauler DP. Clinical therapeutics of adrenal disorders. Am J Med 1972, 53: 673-84.5 Kenny FM, Preeyasombat C, Migeon CJ. Cortisol production rate. II. Normal infants, children, and adults. Pediatrics, 1996: 37 (Suppl. 1) 34-42.6 Kenny FM, Taylor FH, Richards C. Reference standards for cortisol production and 17-hydroxy-corticosteroid extrection during growth: variation in the pattern of excretion of radiolabeled cortisol metabolites. Metabolism 1970, 19 ( Suppl. 4): 280-90.7 Petersen KE. The production of cortisol and corticosterone in children. Acta Paediatr Scand 1980, (Suppl. 281): 2-38.8 Cope CL, Black EG (1958).The behaviour of 14C-cortisol and estimation of cortisol production rate in man. Clin Sci 1958, 17: 147-55.9 Esteban NV, Loughlin T, Yergey AL et al. Daily cortisol production rate in Man Determined by Stable Isotope Dilution/Mass Spectrometry. J Clin Endocrinol Metab 1991, 71: 39-45.10 Oelkwers W. Adrenal Insufficiency. N Engl J Med 1996, 335: 1206-1212.11 Khalid BAK, Burke CW, Hurley DM, Funder JW, Stockigt JR. Steroid replacement in Addison’s disease and in subjects adrenalectomized for Cushing’s disease: Comparison of various glucocorticoids. J Clin Endocrinol Metab 1982, 55: 551-559.12 Groves RW, Toms GC, Houghton BJ, Monson JP. Corticosteroid replacement therapy: twice or thrice daily J R Soc Med 1988, 81: 514-6.13 Howlett TA. An assessment of optimal hydrocortisone replacement therapy. Clin Endocrinol 1997, 46: 263-268.14 Riedel M, Wiese A, Schurmeyer TH, Brabant G. Quality of life in patients with Addison’s disease: effects of different cortisol replacement modes. Exp Clin Endocrinol 1993 101: 106-11.15 Wichers M, Springer W, Bidlingmaier F, Klingmüller D. The influence of hydrocortisone substitution on the quality of life and parameters of bone metabolism in patients with secondary hypocortisolism. Clin Endocrinol 1999, 50: 759-765.16 Lovas K, Loge JH, Husebye ES. Subjective health status in Norwegian patients with Addison’s disease. Clin Endocrinol 2002, 56: 581-588.17 Alonso J, Prieto L, Antó JM. The Spanish version of the Nottingham Health Profile: a review of adaptation and instrument characteristics. Qual Life Res 1994, 3: 385-393.18 Peacey SR, Guo CY, Robinson AM et al..Glucocorticoid replacement therapy: are patients over treated and does it matter Clin Endocrinol 1997, 46: 255-261.19 Feek CM, Ratcliffe JG, Seth J, Gray CE, Toft AD & Irvine WJ. Patterns of plasma cortisol and ACTH concentrations in patients with Addison’s disease treated with conventional corticosteroid replacement. Clin Endocrinol 1981, 14: 451-458.20 Trainer PJ, Mc Hardy KC, Harvey RD, Reid IW. Urinary free cortisol in the assessment of Hydrocortisone replacement therapy. Horm Metab Res 1993, 25: 117-120.21 Arlt W, Callies F, Van Vlijmen JC et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med 1999, 341: 1013-1020.22 Hunt JP, Gurnell EM, Huppert FA et al. Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison’s disease in a randomized, double blind trial. J Clin Endocrinol Metab 2000, 85: 4650-4656.23 Devogelaer JP, Crabbe J & Nagant de Deuxchaisnes C. Bone mineral density in Addison disease: evidence of an effect of adrenal androgens on bone mass. Br Med J 1987, 294: 798-800.24 Florkowski CM, Holmes SJ, Elliot JR, Donald RA, Espiner EA Bone mineral density is reduced in female but not male subjects with Addison’s disease. N Z Med J 1994, 107: 52-53.25 Zelissen PMJ, Croughs RJM, van Rijk PP, Raymakers JA. Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease. Ann Intern Med 1994, 120: 207-210.26 Garbe E, LeLorier J, Boivin JF, Suissa S. Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids. Lancet 1997, 350: 979-982.27 Li Voon Chong JSW, Sen J, Johnson Z, Kyle G, MacFarlane IA. Hydrocortisone replacement regimen dosage influences intraocular pressure in patients with primary and secondary hypocortisolism. Clin Endocrinol 2001, 54: 267-271.28 Al-Shoumer KAS, Beshyah SA, Niththyananthan R, Johnson DJ. Effect of glucocorticoid replacement therapy on glucose tolerance and intermediary metabolites in hypopituitary adults. Clin Endocrinol 1995, 47: 37-41.29 Monson JP. The assessment of glucocorticoid replacement therapy. Clin Endocrinol 1997, 46: 269-270.